ASH 2020 | Cilta-cel in R/R myeloma: preliminary results from CARTITUDE-1
Deepu Madduri, MD, Icahn School of Medicine at Mount Sinai, New York, NY, presents preliminary data from the ongoing Phase Ib/II CARTITUDE-1 study (NCT03548207) of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy product, in 97 patients with relapsed/refractory (R/R) multiple myeloma. The Phase Ib portion of the study indicated that cilta-cel had a manageable safety profile at the recommended Phase II dose of 0.75×10^6 CAR T-cells/kg. Results from the Phase II portion using this dose demonstrated that single treatment with cilta-cel yielded early, deep and durable responses in heavily pretreated patients with R/R multiple myeloma, with an overall response rate (ORR) of 97%, a stringent complete response (CR) rate of 67% and a median progression-free survival (PFS) of at least one year. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Deepu Madduri, MD, has received research support from Regeneron Pharmaceuticals, Inc., Amgen, Allogene, Celgene, Bristol Myers Squibb and Janssen; has done consultancy work with Bristol Myers Squibb, Celgene, GlaxoSmithKline, Kinevant, Janssen, Legend, Millennium/Takeda and Sanofi Genzyme; and has participated in scientific advisory boards with Bristol Myers Squibb, Celgene, GlaxoSmithKline, Kinevant, Janssen, Legend and Sanofi Genzyme.
